CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing Through PIM1 in PIK3CA-Mutant Gastric Cancer

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2023 Jul 26

PMID 37493631

Authors

Lyla J Stanland

Hazel X Ang

Jacob P Hoj

Yunqiang Chu

Patrick Tan

Kris C Wood

Micah A Luftig

Affiliations

Soon will be listed here.

Abstract

Implications: Loss of either NEDD9 or BCL-XL confers hypersensitivity to PI3K-alpha inhibition whereas loss of CBFB confers resistance through a CBFB/PIM1 signaling axis.

Citing Articles

Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review.

Corallo S, Lasagna A, Filippi B, Alaimo D, Tortorella A, Serra F Pathogens. 2024; 13(9).

PMID: 39338919 PMC: 11435077. DOI: 10.3390/pathogens13090728.

Li Y, Li H, Xiang Z Heliyon. 2024; 10(6):e27599.

PMID: 38510044 PMC: 10951579. DOI: 10.1016/j.heliyon.2024.e27599.

Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.

Morgos D, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S Int J Mol Sci. 2024; 25(3).

PMID: 38339127 PMC: 10856016. DOI: 10.3390/ijms25031848.

Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.

Wang H, Liu Y, Deng L, Jiang K, Yang X, Wu X Cancer Cell Int. 2023; 23(1):187.

PMID: 37649078 PMC: 10469937. DOI: 10.1186/s12935-023-03032-3.

References

Wang L, Doherty G, Judd A, Tao Z, Hansen T, Frey R . Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor. ACS Med Chem Lett. 2020; 11(10):1829-1836. PMC: 7549103. DOI: 10.1021/acsmedchemlett.9b00568. View

Arrouchi H, Lakhlili W, Ibrahimi A . A review on PIM kinases in tumors. Bioinformation. 2019; 15(1):40-45. PMC: 6651028. DOI: 10.6026/97320630015040. View

Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S . IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis. 2018; 9(10):944. PMC: 6148236. DOI: 10.1038/s41419-018-1025-8. View

Anderson G, Winter P, Lin K, Nussbaum D, Cakir M, Stein E . A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Rep. 2017; 20(4):999-1015. PMC: 5567854. DOI: 10.1016/j.celrep.2017.07.006. View

Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J . Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020; 13(1):118. PMC: 7470446. DOI: 10.1186/s13045-020-00956-5. View

Kundu M, Liu P . Function of the inv(16) fusion gene CBFB-MYH11. Curr Opin Hematol. 2001; 8(4):201-5. DOI: 10.1097/00062752-200107000-00004. View

Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H . Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition. Breast Cancer Res. 2016; 18(1):41. PMC: 4820873. DOI: 10.1186/s13058-016-0697-1. View

Zhang Z, Christin J, Wang C, Ge K, Oktay M, Guo W . Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation. Cell Rep. 2016; 16(12):3146-3156. PMC: 5069998. DOI: 10.1016/j.celrep.2016.08.048. View

Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B . The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698:120-128. DOI: 10.1016/j.gene.2019.02.076. View

10.

Wang M, Li J, Huang J, Luo M . The Predictive Role of Mutation Status on Inhibitors in Breast Cancer Therapy: A Systematic Review and Meta-Analysis. Biomed Res Int. 2020; 2020:1598037. PMC: 7238354. DOI: 10.1155/2020/1598037. View

11.

Zhang M, Jang H, Nussinov R . PI3K inhibitors: review and new strategies. Chem Sci. 2020; 11(23):5855-5865. PMC: 7472334. DOI: 10.1039/d0sc01676d. View

12.

Meister K, Godse N, Khan N, Hedberg M, Kemp C, Kulkarni S . HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Sci Rep. 2019; 9(1):9130. PMC: 6591241. DOI: 10.1038/s41598-019-45589-y. View

13.

Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z . Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death Dis. 2018; 9(2):123. PMC: 5833539. DOI: 10.1038/s41419-017-0132-2. View

14.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

15.

Anderson G, Wardell S, Cakir M, Crawford L, Leeds J, Nussbaum D . PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med. 2016; 8(369):369ra175. PMC: 5626456. DOI: 10.1126/scitranslmed.aae0348. View

16.

Bhattacharya B, Akram M, Balasubramanian I, Tam K, Koh K, Yee M . Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol Ther. 2012; 13(1):34-42. DOI: 10.4161/cbt.13.1.18437. View

17.

Singh M, Cowell L, Seo S, ONeill G, Golemis E . Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007; 48(1):54-72. PMC: 1976382. DOI: 10.1007/s12013-007-0036-3. View

18.

Liu P, Liu J, Sun S, Gao Y, Ai Y, Chen X . CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML. Front Cell Dev Biol. 2021; 9:675424. PMC: 8321512. DOI: 10.3389/fcell.2021.675424. View

19.

Xu M, Xu L, Wang Y, Dai G, Xue B, Liu Y . BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584. Aging (Albany NY). 2020; 12(19):19147-19158. PMC: 7732329. DOI: 10.18632/aging.103723. View

20.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X . Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1):26. PMC: 6379961. DOI: 10.1186/s12943-019-0954-x. View